Yang Guang, Xu Jing, Chi Xiu-Lian, Zang Chun-Xin, Que Ling
State Key Laboratory Breeding Base of Dao-di Herbs, National Resource Center for Chinese Materia Medica, China Academy of Chinese Medical Sciences, Beijing 100700, China.
Biodiversity Research Center, Chinese Research Academy of Environmental Sciences, Beijing 100012, China.
Zhongguo Zhong Yao Za Zhi. 2018 Jan;43(2):396-400. doi: 10.19540/j.cnki.cjcmm.20171030.005.
The three objectives of the Convention on Biological Diversity (CBD) are the conservation of biological diversity, the sustainable use of its components and the fair and equitable sharing of benefit sarising from the utilization of genetic resources.The Nagoya Protocol significantly advances the CBD's third objective by providing a strong basis for greater legal certainty and transparency for both providers and users of genetic resources.In June 2016, the Chinese government approved the accession to the Nagoya Protocol. The implementation of the Nagoya Protocol is bound to greatly influence the traditional Chinese medicine (TCM) as its development relies on medical biological genetic resources.Both the protection and access of medical biological genetic resources and its related traditional knowledge and the introduction, breeding, biosynthesis and the extraction and modification of effective components of medicinal organism are with the prescribed scope of the Nagoya Protocol. In this study, we simply introduce the background and main contents of the Nagoya Protocol in first. We then explore the relationship between the Nagoya Protocol and the TCM.We also analyze the positive effects on the TCM for China to be one of the parties of the Nagoya Protocol and finally make some proposals for better implementation of the Nagoya Protocol.This study has certain reference significance to the resource economy and management of TCM.
《生物多样性公约》(CBD)的三个目标是保护生物多样性、可持续利用其组成部分以及公平公正地分享利用遗传资源所产生的惠益。《名古屋议定书》为遗传资源的提供者和使用者提供了更强的法律确定性和透明度,极大地推进了《生物多样性公约》的第三个目标。2016年6月,中国政府批准加入《名古屋议定书》。《名古屋议定书》的实施必然会对传统中医药(TCM)产生重大影响,因为其发展依赖于医学生物遗传资源。医学生物遗传资源及其相关传统知识的保护与获取,以及药用生物体有效成分的引进、培育、生物合成和提取与改性均在《名古屋议定书》的规定范围内。在本研究中,我们首先简要介绍《名古屋议定书》的背景和主要内容。然后探讨《名古屋议定书》与传统中医药之间的关系。我们还分析了中国成为《名古屋议定书》缔约方之一对传统中医药的积极影响,最后就更好地实施《名古屋议定书》提出一些建议。本研究对传统中医药的资源经济与管理具有一定的参考意义。